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Abstract
Alzheimer’s disease (AD) is the most common form of dementia and is phenotypically heterogeneous. APOE
is a triallelic gene which correlates with phenotypic heterogeneity in AD. In this work, we determined the
effect of APOE alleles on the disease progression timeline of AD using a discriminative event-based model
(DEBM). Since DEBM is a data-driven model, stratification into smaller disease subgroups would lead to
more inaccurate models as compared to fitting the model on the entire dataset. Hence our secondary aim is
to propose and evaluate novel approaches in which we split the different steps of DEBM into group-aspecific
and group-specific parts, where the entire dataset is used to train the group-aspecific parts and only the
data from a specific group is used to train the group-specific parts of the DEBM. We performed simulation
experiments to benchmark the accuracy of the proposed approaches and to select the optimal approach.
Subsequently, the chosen approach was applied to the baseline data of 417 cognitively normal, 235 mild
cognitively impaired who convert to AD within 3 years, and 342 AD patients from the Alzheimers Disease
Neuroimaging Initiative (ADNI) dataset to gain new insights into the effect of APOE carriership on the
disease progression timeline of AD. In the risk group (with APOE ε3− ε4 or ε4− ε4), the model predicted
with high confidence that CSF Amyloid β and the cognitive score of Alzheimer’s Disease Assessment Scale
(ADAS) are early biomarkers. Hippocampus was the earliest volumetric biomarker to become abnormal,
with the molecular layer of the hippocampus becoming abnormal even before the CSF Phosphorylated Tau
(PTAU) biomarker. In the neutral group (with APOE ε3−ε3) the model predicted a similar ordering among
CSF biomarkers. However, the volume of the fusiform gyrus was identified as one of the earliest volumetric
biomarker along with the hippocampus subparts of Fissure and Parasubiculum. While the findings in the
risk and neutral groups fit the amyloid cascade hypothesis, the finding in the protective group (with APOE
ε2− ε2 or ε2− ε3) did not. The model predicted, with relatively low confidence, CSF Neurogranin as one of
the earliest biomarkers along with cognitive score of Mini-Mental State Examination (MMSE). Amyloid β
was found to become abnormal after PTAU. The presented models could aid understanding of the disease,
and in selecting homogeneous group of presymptomatic subjects at-risk of developing symptoms for clinical
trials.
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1. Introduction
Dementia affects roughly 5% of the world’s el-
derly population of whom 60 − 70% are affected
by Alzheimer’s Disease (AD), which is the most
common form of dementia (World Health Organiza-
tion, 2017). There are several neurobiological sub-
types of AD (Ferreira et al., 2020) and each sub-
type potentially needs a different strategy to pre-
vent or slow the progression of AD. Understand-
ing the pathophysiological processes in AD is thus
crucial for selecting novel preventive or therapeutic
targets for clinical trials of disease modifying treat-
ments, identifying target groups for such trials and
tracking the disease progression in patients.
While several studies have looked into the patho-
physiology of AD (Jack Jr. et al., 2013; Bloom,
2014; Weigand et al., 2019), it is still not completely
understood. Although it has been observed that
AD is phenotypically heterogeneous (Murray et al.,
2011; Au et al., 2015; Patterson, 2018) with po-
tentially different pathways for disease progression,
these pathways remain unclear. There is hence a
need to understand the phenotypic heterogeneity in
AD while leveraging neuroimaging, fluid and cogni-
tive biomarkers.
APOE is a triallelic gene in which the ε2 allele
reduces the risk of AD (van der Lee et al., 2018), the
ε3 allele acts as a reference allele and the ε4 allele is
a major genetic risk factor of AD (Saunders et al.,
1993; Kim et al., 2009; Genin et al., 2011). APOE
has been shown to correlate with phenotypic het-
erogeneity in AD (Weintraub et al., 2019). Hence
we hypothesize that the pathophysiology of AD can
be better understood when considering the effect of
APOE carriership on biomarker changes.
In the context of data-driven methods for un-
derstanding AD pathophysiology, disease progres-
sion models have been used to study the trajec-
tories of individual biomarkers (Jedynak et al.,
2012; Schiratti et al., 2015; Lorenzi et al., 2017)
as well as their progression with respect to each
other (Fonteijn et al., 2012; Venkatraghavan et al.,
2017; Young et al., 2014; Huang and Alexander,
2012). Unlike typical machine learning approaches,
these models are interpretable by design and pro-
vide insight for understanding the mechanisms of
and implementation of ADNI and/or provided data but
did not participate in analysis or writing of this report.
A complete listing of ADNI investigators can be found
at: http://adni.loni.usc.edu/wp-content/uploads/how_
to_apply/ADNI_Acknowledgement_List.pdf
disease progression. Event-based models (EBMs)
are a class of such interpretable disease progression
models that estimate the timeline of neuropatho-
logic change during AD progression using cross-
sectional data (Fonteijn et al., 2012; Venkatragha-
van et al., 2019a).
Our primary aim is to use the discriminative
event-based model (DEBM), which was shown
to be more accurate than previously proposed
EBMs (Venkatraghavan et al., 2019a), to under-
stand the effect of different APOE alleles on the
disease timeline of AD. To shed light on different as-
pects of neurodegeneration and identify the earliest
brain regions affected, we included commonly stud-
ied cerebrospinal fluid (CSF) biomarkers, cognitive
scores, and volumetric biomarkers from neuroimag-
ing including those of hippocampus subfields. Hip-
pocampus subfields were included in our model
because while Hippocampus neuronal dysfunction
is quite commonly studied to be affected in AD,
it is not a homogenous structure, and subfields
could be affected differentially due to APOE carri-
ership (Mueller and Weiner, 2009).
The default approach for estimating the disease
progression timeline would be to stratify the pop-
ulation based on their APOE ε2− 4 carrier status
and independently train the DEBM model on the
stratified populations (Young et al., 2014). How-
ever, since DEBM is a data-driven model, strati-
fication into smaller groups would lead to less ac-
curate models than those obtained by the original
method on the entire dataset. Hence our secondary
aim is to propose and evaluate a novel approach
in which we split the different steps of DEBM into
group-aspecific and group-specific parts, where the
entire dataset is used to train the group-aspecific
parts and only the data from a specific group is
used to train the group-specific parts of the DEBM.
We present two different variations of this approach
and we hypothesize that the optimal split of the
DEBM steps into the group-aspecific and group-
specific parts would result in better accuracy of the
estimated disease progression timeline. Since the
ground-truth timelines are unknown in a clinical
setting, we evaluate the accuracy of the proposed
variations using simulation experiments and we se-
lect the optimal method for the analysis on the ef-
fect of APOE on the AD progression timeline on
patient data.
To summarize, our contributions in this paper in-
clude proposing and evaluating a novel approach for
using DEBM in stratified populations and estimat-
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ing a comprehensive timeline of AD progression, in
terms of biomarker changes, in the presence of dif-
ferent APOE alleles.
2. Methods
An introduction to the DEBM model (Venka-
traghavan et al., 2019a) is provided in Section 2.1.
In Section 2.2 we propose our novel approach for
using DEBM in stratified populations with its two
variations.
2.1. Discriminative event-based modeling
In a cross-sectional dataset (X) of M subjects,
including cognitively normal individuals (CN), sub-
jects with mild cognitive impairment (MCI) and
patients with AD, let Xj denote a measurement
of biomarkers for subject j ∈ [1,M ], consisting
of scalar biomarker values xj,i for i ∈ [1, N ]. x·,i
denotes the i-th biomarker for any unspecified j.
DEBM estimates the posterior probabilities of indi-
vidual biomarkers being abnormal. These posterior
probabilities are used to estimate the ordering of
biomarker changes for each subject independently.
The central ordering and disease progression time-
line for the entire dataset are estimated based on
these subject-specific orderings. The resulting dis-
ease progression timeline is used for assessing the
severity of disease in an individual based on his/her
biomarker values. Figure 1 shows the different steps
involved in DEBM.
Step 1 - Mixture Modeling: As AD is char-
acterized by a cascade of neuropathological changes
that occurs over several years, presymptomatic CN
subjects can have some abnormal biomarker val-
ues. On the other hand, in atypical AD subjects, a
proportion of biomarkers may still have normal val-
ues, especially in patients at an early disease stage.
Hence clinical labels cannot directly be propagated
to individual biomarkers to label normal and ab-
normal biomarker values. We shall refer to this as
biomarker label noise in the rest of the paper. In
order to estimate the posterior probabilities of in-
dividual biomarkers being abnormal, DEBM, sim-
ilar to previously proposed EBMs Fonteijn et al.
(2012); Huang and Alexander (2012); Young et al.
(2014), fits a Gaussian mixture model (GMM) to
construct the normal / pre-event probability den-
sity function (PDF), p(x·,i|¬Ei), and abnormal /
post-event PDF, p(x·,i|Ei). Event Ei in this nota-
tion is used to denote the corresponding biomarker
becoming abnormal and ¬Ei denotes the correspon-
nding biomarer being normal. The aforementioned
PDFs can be expressed as:
p(x·,i|¬Ei) = N (µi,¬E ;σi,¬E) (1)
p(x·,i|Ei) = N (µi,E ;σi,E) (2)
Where, N (µ, σ) is the normal distribution with
mean µ and standard deviation σ.
For estimating these parameters robustly in the
presence of biomarker label noise, the normal and
abnormal PDF estimates are first initialized using
the mean and standard deviations after truncating
the overlapping tails of the observed distributions
in CN and AD subjects. This can be observed in
Figure 2, where the initialization is performed only
based on the non-overlapping parts of green and
red curves, while the overlapping part is left out
to account for biomarker label noise. At this stage
of GMM initialization, MCI subjects are left out
as well, because it is unsure a priori whether their
biomarkers are normal or abnormal. The result-
ing initialized PDFs are denoted as p̂(x·,i|¬Ei)) and
p̂(x·,i|Ei).
This is followed by an alternating GMM maxi-
mum likelihood optimization scheme until both the
Gaussian parameters as well as the mixing parame-
ters converge. All the subjects, including MCI, are
used for GMM optimization. After convergence,
these Gaussians are used to represent the PDFs
p(x·,i|¬Ei) and p(x·,i|Ei). The mixing parame-
ters (θi) are used as prior probabilities to convert
these PDFs to posterior probabilities p(¬Ei|x·,i)
and p(Ei|x·,i). Figure 2 shows an overview of this
optimization scheme.
Step 2 - Subject-specific Orderings:
p(Ei|xj,i)∀i are used to estimate the subject-
specific orderings sj . sj is established such
that:
sj 3 p(Esj(1)|xj,sj(1)) > ...
> p(Esj(N)|xj,sj(N)) (3)
Step 3 - Central Ordering: DEBM com-
putes the central event ordering S from the subject-
specific estimates sj . To describe the distribution
of sj , a generalized Mallows model is used (Fligner
and Verducci, 1988). The central ordering is de-
fined as the ordering that minimizes the sum of
distances to all subject-specific orderings sj , with
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Figure 1: Overview of the steps involved in DEBM. Input for the DEBM model is a cross-sectional dataset X with M subjects
and various biomarkers (A,B,C and D) representing different aspects of neuro-degeneration. Using Gaussian mixture modeling
(GMM), mixing parameters (θi) and probability density functions of normal (p(x·,i|¬Ei)) and abnormal (p(x·,i|Ei)) levels
are estimated for each biomarker. This is followed by the estimation of subject-specific orderings (sj), for each subject in
the dataset. Disease progression timeline consisting of central ordering (S) and event-centers (λ) are estimated based on
these subject-specific orderings. Based on the constructed disease progression timeline, patient stages (Υj) of subjects in an
independent test-set can be estimated.
Figure 2: Overview of GMM optimization in DEBM.
probabilistic Kendall’s Tau being the distance mea-
sure (Venkatraghavan et al., 2019a). While S de-
notes the sequence of biomarker events, the relative
position of these events (event-centers) in a nor-
malized scale of [0, 1] is denoted by the vector λ.
The pair {S, λ} together forms a disease progres-
sion timeline.
Step 4 - Patient Staging: Once the disease
progression timeline is created, subjects in an inde-
pendent test set (T ) can be placed on this timeline
to estimate disease severity. This is achieved by
converting the biomarker values of the test subjects
to posterior probabilities p(Ei|xj,i), ∀j ∈ T . These
can be used to estimate disease severities in test
subjects by first estimating the conditional distri-
bution p(i|S,Xj), which estimates the probability
that the first i events of S have occurred for a test-
subject and the rest are yet to occur.
p (i|S,Xj) ∝
i∏
l=1
p
(
ES(l)|xj,S(l)
)×
N∏
l=i+1
p
(¬ES(l)|xj,S(l)) (4)
The patient stage of a test subject (Υj) is de-
fined as the expectation of λ(i) with respect to the
conditional distribution p(i|S,Xj).
Υj =
∑N
i=1 λ(i)p(i|S,Xj)∑N
i=1 p(i|S,Xj)
(5)
2.2. Group-specific and group-aspecific parts of
DEBM
We propose extensions of DEBM for stratified
populations, i.e., when the dataset X can be sub-
divided in groups g ∈ [1, G], based on, e.g., geno-
type or phenotype of the subjects. Since DEBM
is a data-driven model, data stratification into
smaller groups would lead to more inaccurate mod-
els (Venkatraghavan et al., 2019a). To obtain better
DEBM accuracies in such scenario, we propose to
co-train DEBM for estimating disease timelines ∀g
by splitting DEBM into group-aspecific and group-
specific parts. The group-aspecific parts of DEBM
are estimated using the entire dataset and group-
specific parts are estimated for each group indepen-
dently.
We first discuss the default way of indepen-
dently training DEBM in the different groups and
then propose two different approaches for split-
ting DEBM into group-aspecific and group-specific
parts.
Approach 1: Independent DEBM
In this default approach, each group is considered
as an independent dataset and the disease progres-
sion timeline in each group is estimated indepen-
dently. GMM in such a scenario is illustrated in
Figure 3a.
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Approach 2: Coupled DEBM
DEBM→
{
p(x·,i|¬Ei), p(x·,i|Ei) group-aspecific
θi,g, {Sg, λg}, group-specific
(6)
In this approach, we assume that the different
groups share the normal and abnormal PDFs, but
the ordering in which these biomarkers become
abnormal are different. The mixing parameters
(θi,g) are considered as group-specific part of the
DEBM algorithm because the proportion of sub-
jects with normal and abnormal biomarker values
in each group g is correlated with the position of the
biomarker along the ordering Sg, which we expect
to be different in each group.
Hence, in our approach, we modify the alternat-
ing GMM optimization scheme to jointly optimize
the GMM parameters of multiple groups. First, the
GMM algorithm is initialized without considering
the groups, as explained in Section 2.1. Secondly, as
with the default DEBM, Gaussian parameters and
mixing parameters are alternately optimized. In
contrast in coupled DEBM, the Gaussian parame-
ters are estimated jointly for all groups, while mix-
ing parameters are estimated separately for each
group. This has been illustrated in Figure 3b.
Once the GMM optimization has been per-
formed, Sg and λg are estimated in each group.
Patient staging (Υj) of the test-subjects in group
g are computed based on the disease progression
timeline {Sg, λg}.
Approach 3: Co-init DEBM
DEBM→

p̂(x·,i|¬Ei), p̂(x·,i|Ei) group-aspecific
pg(x·,i|¬Ei), pg(x·,i|Ei) group-specific
θi,g, {Sg, λg} group-specific
(7)
In this approach, we assume that the differ-
ent groups do not share the normal and abnor-
mal PDFs, but that they are close to each other.
Hence, in co-init DEBM, we relax the constraint
on p(x·,i|¬Ei) and p(x·,i|Ei) and instead con-
sider the initialized values of normal and abnor-
mal PDFs (p̂(x·,i|¬Ei) and p̂(x·,i|Ei)) to be group-
aspecific part of DEBM. We estimate pg(x·,i|¬Ei)
and pg(x·,i|Ei) independently for each group. This
is illustrated in Figure 3c.
As with the previous approach, Sg, λg and the
patient staging of the test-subjects in group g are
computed independently for each group.
(a) GMM in independent DEBM
(b) GMM in Coupled DEBM
(c) GMM in Co-init DEBM
Figure 3: Overview of GMM optimization strategies in the
different approaches for DEBM analysis in stratified popula-
tions. (a) The default approach in which GMM in each group
is trained independently. (b) GMM in coupled DEBM, where
the different groups share the Gaussian parameters, but the
mixing parameters are estimated independently. (c) GMM
in co-init DEBM in which the different groups are jointly ini-
tialized before the GMM optimization, but the optimization
is done independently for each group.
3. Experiments
Section 3.1 describes the experiments to evaluate
the proposed DEBM approaches on a stratified pop-
ulation. Since ground-truth orderings are unknown
in real clinical data, we use simulated datasets for
evaluating the methods. After evaluating the pro-
posed approaches, we select the best approach for
analyzing the effect of APOE on AD progression
using subjects from the Alzheimer’s Disease Neu-
roimaging Initiative (ADNI) database. Section 3.2
descibes the details of these experiments.
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3.1. Simulation Experiments
We used the framework developed by Young et al.
(2015) for simulating cross-sectional data consisting
of scalar biomarker values for CN, MCI and AD
subjects in two groups. In this framework, disease
progression in a subject is modeled by a series of
biomarker changes representing the temporal cas-
cade of biomarker abnormality as estimated by an
EBM. Individual biomarker trajectories are repre-
sented by sigmoids varying from the biomarker’s
normal value to its abnormal value. To account for
inter-subject variability, the normal and abnormal
values for different subjects are drawn randomly
from Gaussian distributions.
The simulation dataset used in our experiments
are based on a set of seven biomarkers as described
in the simulation experiments of Venkatraghavan
et al. (2019a). The simulated datasets were strat-
ified into two groups, with each group having its
own distinct disease progression patterns. There
are two ways in which the progression of disease
in the groups can differ: 1. difference in ground-
truth orderings S1 and S2; 2. difference in the
abnormal biomarker PDFs in the two groups i.e.
p1(x·,i|Ei) and p2(x·,i|Ei). Each of these differ-
ences could affect the accuracy of the proposed ap-
proaches. Hence, we evaluated the proposed ap-
proaches in the presence of each of these differences.
Normalized Kendall’s Tau distance between the es-
timated ordering (S) and the ground-truth ordering
(Sgt) was used as an evaluation measure in these
experiments:
εS = K(S,Sgt)/(N2 ) (8)
where K(A,B) is the number of swaps required to
obtain ordering B from ordering A.
The normalization ensures that εS falls in the
range [0, 1], with 0 as the distance when the two
orderings are the same, and 1 as the distance when
the two orderings are the reverse of each other.
Experiment 1: The first simulation experiment
studied the effect of the difference in ordering be-
tween the two groups. The ordering in the first
group (Group 1) was fixed and the ordering in the
second group (Group 2) was selected randomly such
that the normalized Kendall’s Tau distance between
the two groups was a fixed number, say εO. εO was
varied from 0 to 1 in steps of 0.2. The number of
subjects in Group 2 was kept constant at 900. The
number of subjects in Group 1 was varied from 100
to 900 in steps of 200, to study how the different
approaches perform in small as well as large groups.
The normal and abnormal biomarkers levels in the
two groups were sampled from the same Gaussian
distribution for this experiment. We generated 50
random repetitions of the simulated datasets, and
reported mean and standard deviation of εS for
independent DEBM, coupled DEBM, and co-init
DEBM in groups 1 and 2.
Experiment 2: This experiment studied the
performance of the proposed approaches with the
µg,i,E parameter of the pg(x·,i|Ei) distribution be-
ing different in the two groups. µ1,i,E was fixed,
and µ2,i,E was varied such that the difference
µ2,i,E − µ1,i,E (εG) was one of {−0.2d, 0,+0.2d}
where d = µ1,i,E − µ1,i,¬E . 0 is considered the ref-
erence level, where the abnormal Gaussians are the
same in the two groups. µg,i,¬E were kept the same
in the two groups. Hence, when εG = −0.2d, the
abnormal biomarker levels are closer to the normal
biomarker levels in Group 2 than in Group 1. This
results in Group 2 biomarkers being weaker than
their Group 1 counterparts when εG = −0.2d and
stronger when εG = +0.2d. The number of sub-
jects in Group 2 was kept a constant at 900, while
the subjects in Group 1 increased from 100 to 900.
εO between the two groups was fixed at 0.4. We
again generated 50 random repetitions of the sim-
ulated datasets, and reported mean and standard
deviation of εS for coupled DEBM, co-init DEBM
and DEBM.
These experiments were used to evaluate the dif-
ferent approaches mentioned in Section 2 and select
the best method for analyzing the effect of APOE
alleles in AD progression.
3.2. Studying the effect of APOE
We considered the baseline measurements from
417 CN, 235 MCI converters and 342 AD subjects in
ADNI1, ADNIGO and ADNI2 studies2. The MCI
converters are subjects who had MCI at baseline
but converted to AD within 3 years of baseline mea-
surement. We excluded subjects with significant
memory concerns (without a diagnosis of AD or
2The ADNI was launched in 2003 as a public-private part-
nership, led by Principal Investigator Michael W. Weiner,
MD. The primary goal of ADNI has been to test whether
serial magnetic resonance imaging (MRI), positron emission
tomography (PET), other biological markers, and clinical
and neuropsychological assessment can be combined to mea-
sure the progression of mild cognitive impairment (MCI) and
early Alzheimers disease (AD). For up-to-date information,
see www.adni-info.org.
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Demographics
Diagnosis CN MCIc AD
n 417 235 342
APOE
2?/33/?4
57/244/110 6/66/156 12/101/219
Sex M/F 209/208 145/90 189/153
Age [yrs.]
(µ± σ)
74.8± 5.7 73.7± 7.0 75.0± 7.8
Edu [yrs.]
(µ± σ)
16.3± 2.7 15.9± 2.7 15.2± 3.0
Table 1: Demographics for the used population. 2? repre-
sents the subjects with protective APOE alleles ε2, 2 and
ε2, 3. 33 represents the subjects with reference APOE al-
lele ε3, 3. ?4 represents the subjects with risk APOE alleles
ε3, 4 and ε4, 4. Subjects with both protective and risk al-
lele ε2, 4 were excluded from this study (n=34). Edu. is an
abbreviation used for Education.
MCI) and MCI non-converters in our experiments
to select a more phenotypically homogeneous group
of subjects with prevalent or incident AD. In each
of the experiments, the dataset was divided into
three groups (protective, neutral and risk) based
on the subject’s APOE carriership. The protective
group consisted of subjects with APOE ε2, 2 and
ε2, 3 (van der Lee et al., 2018). The neutral group
consisted of subjects with APOE ε3, 3. The risk
group consisted of subjects with APOE ε3, 4 and
ε4, 4 (Saunders et al., 1993; Kim et al., 2009; Genin
et al., 2011). Subjects with APOE ε2, 4 (n=34)
were not included in either group because of the
presence of both protective and risk alleles.
Subject demographics and their APOE carrier-
ships are summarized in Table 1. The modalities
considered were structural imaging (T1-weighted
MRI) biomarkers, biomarkers extracted from cere-
brospinal fluid (CSF), and cognitive biomarkers.
Details of the MRI acquisition protocols of ADNI
can be found in Jack Jr. et al. (2008, 2015).
Imaging biomarkers were estimated from T1-
weighted MRI scans analysed with FreeSurfer soft-
ware v6.0 cross-sectional stream and outputs were
visually checked. We assumed a symmetric pattern
of atrophy in AD and averaged imaging biomarkers
between the left and right hemisphere.
Experiment 3: For this experiment, the se-
lected imaging biomarkers were: volumetric mea-
sures of the hippocampus, entorhinal cortex,
fusiform gyrus, middle-temporal gyrus and pre-
cuneus, together with whole brain volume and ven-
tricles (Archetti et al., 2019; Frisoni et al., 2010;
Vemuri and Jack, 2010). The selected CSF based
Biomarker Availability
Biomarker Protective
(N = 75)
Neutral
(N = 411)
Risk
(N = 485)
Imaging 74 408 481
ABETA 57 301 357
PTAU 57 301 357
TAU 57 299 348
NG 21 113 131
NFL 23 118 137
MMSE 75 411 485
ADAS 74 410 477
Table 2: Biomarker availability in number of subjects in the
protective, neutral and risk groups.
biomarkers were: CSF concentrations of Amyloid-
(ABETA), total Tau (TAU) and phosphorylated
Tau (PTAU) proteins (Blennow and Hampel, 2003;
Blennow et al., 2010), Neurogranin (Thorsell et al.,
2010) and Neurofilament light chain (Jin et al.,
2019; de Wolf et al., 2020). Mini mental state exam-
ination (MMSE) and Alzheimer’s Disease Assess-
ment Scale - Cognitive (13 items) (ADAS13) were
used as cognitive biomarkers. The availability of
these multimodal biomarkers in the ADNI database
is summarized in Table 2.
For the 12 selected biomarkers, we estimated
the disease timelines in the three aforementioned
groups using the method selected after simulation
experiments. We studied the positional variance
of the estimated orderings by creating 100 boot-
strapped samples of the data.
Experiment 4: The above experiment was re-
peated by including volumes of subfields of hip-
pocampus (Iglesias et al., 2015) as biomarkers in-
stead of considering the entire hippocampus vol-
ume as a single biomarker. We included the
tail of the hippocampus (Tail), Subiculum, CA1,
CA2/3, hilar region of the dentate gyrus (CA4),
hippocampal fissure (Fissure), area 27 in Brod-
mann (1909) (Presubiculum), area 49 in Brod-
mann (1909) (Parasubiculum), Molecular layer of
the subiculum and CA fields (ML), granule cell and
molecular layer of the dentate gyrus (GC ML DG),
and the hippocampus-amygdala transition area
(HATA). We excluded the white matter structures
of Alveus and Fimbria in our analysis.
Experiment 5: In this experiment, we validated
the disease stage (Υj) by computing its correlation
with the subjects’ MMSE and ADAS13 values. We
used a 10-fold cross validation, where the training
set was used to estimate the disease timeline in the
aforementioned groups and the test subjects’ dis-
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ease stage was evaluated by placing them on this
disease timeline. We used the volume-based and
CSF-based biomarkers from Experiment 3, but ex-
cluded MMSE and ADAS13 scores from the model.
4. Results
4.1. Simulations
Experiment 1: Figures 4 (a) and (b) show the
ordering errors (εS) in Group 1 of the simulation
datasets for DEBM, coupled DEBM and co-init
DEBM as a function of number of subjects in Group
1, when εO between the two groups changes from 0
to 1. Figures 4 (c), (d) and (e) show εS in Group
2 of the simulation datasets for the aforementioned
methods, as a function of number of subjects in
Group 1. In our experiments, Group 1 dataset re-
mains the same while Group 2 dataset changes as
εO increase. Hence DEBM results do not change
with change in εO in Figure 4 (a) and (b), whereas
in Figure 4 (c), DEBM results do not change with
increase in number of subjects in Group 1.
It can be seen that both coupled-training meth-
ods (i.e., co-init DEBM and coupled DEBM) out-
perform the default method of independently train-
ing DEBM models. It can also be observed that in
both co-init DEBM and coupled DEBM the order-
ing errors decrease as εO increases and that co-init
DEBM outperforms coupled DEBM for lower val-
ues of εO, whereas the performance is on par with
coupled DEBM for higher values of εO.
Experiment 2: Figures 5 (a) and (b) show εS
in Group 1 and Figures 5 (c), (d) and (e) show
the same in Group 2, when varying εG. Even with
εG 6= 0, coupled training (i.e., co-init DEBM and
coupled DEBM) outperformed the default method
of independently training DEBM models. Co-init
DEBM showed negligible change in the errors when
εG 6= 0. The performance of coupled DEBM in
Group 1 worsened for εG = +0.2d (Figure 5 (a))
and in Group 2 for εG = −0.2d (Figure 5 (d)).
4.2. Studying the effect of APOE
The results in Experiments 1 and 2 show that
the performance of co-init DEBM is more accurate
and robust than coupled DEBM in most scenarios.
We hence analyzed Experiments 3− 5 using co-init
DEBM.
Experiment 3: Figure 6 shows orderings of
CSF, global cognition and volumetric biomarkers
in the APOE based protective, neutral and risk
groups along with their uncertainty estimates. It
can be seen that the uncertainty of the ordering
in the protective group was high. Despite this
uncertainty, some biomarkers (i.e. MMSE, NG
and PTAU) seem to occur earlier than the other
biomarkers in this group.
In the group of subjects with neutral alle-
les, ABETA was very prominently the earliest
biomarker, followed by cognitive scores of MMSE
and ADAS13. Among the CSF biomarkers, PTAU
followed immediately after ABETA, which was in-
turn followed by TAU. NFL and NG were late
biomarkers. Among the structural biomarkers, vol-
umes of fusiform and middle-temporal gyri were the
first to become abnormal, followed by ventricular
volume and wholebrain volume. Hippocampus, pre-
cuneus and entorhinal volumes were late biomarkers
in this group.
In the risk group, the CSF biomarkers followed a
pattern that was similar to that of the neutral alle-
les. The cognitive biomarkers were early biomark-
ers in this group as well. However the ordering in
structural biomarkers was very different from that
in the neutral group. Hippocampus and entorhi-
nal volumes were early biomarkers in this group,
followed by middle-temporal and fusiform gyri vol-
umes. Wholebrain, ventricular and precuneus vol-
umes were late biomarkers.
Experiment 4: Figure 6 shows orderings of
CSF, global cognition and volumetric biomarkers
along with that of Hippocampus subfields in the
APOE based protective, neutral and risk groups
along with their uncertainty estimates. Parasubicu-
lum was an early biomarker in the protective group,
which became abnormal even before MMSE and
NG. Fissure, Tail and Presubiculum followed im-
mediately after that. Subiculum was one of the
late biomarkers.
Fissure and Parasubiculum were early structural
biomarkers for the neutral group as well. This was
followed by dysfunction in CA3 and HATA.
A majority of the Hippocampal subfields were
early biomarkers in the risk group, with ML,
Subiculum and Tail as the three earliest regions.
Experiment 5: The variation of MMSE and
ADAS13 scores with respect to the estimated dis-
ease stages has been plotted in Figure 8, for all three
groups. The patient stages showed a significant cor-
relation with both MMSE and ADAS13 scores. The
correlation coefficients were also comparable in the
three groups.
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(a) (b)
(c) (d) (e)
Figure 4: Experiment 1: The effect of εO (the difference in groundtruth event orderings in the two groups) on the performance
of the proposed methods. The shaded region in these plots represents standard deviation of the error in estimation of the
proposed methods in 50 random iterations of simulations. The plots in (a) and (b) show the ordering errors in Group 1 using
Coupled DEBM and Co-init DEBM with independent DEBM shown in both (a) and (b), as a function of number of subjects
in Group 1. The plots in (c), (d) and (e) show the ordering errors in Group 2 using independent DEBM, Coupled DEBM and
Co-init DEBM respectively as a function of number of subjects in Group 1.
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(a) (b)
(c) (d) (e)
Figure 5: Experiment 2: The effect of εG (difference in abnormal biomarker levels in the two groups), on the performance of
the proposed methods. The shaded region represents standard deviation of the error in 50 random iterations. The plots in (a)
and (b) show the ordering errors in Group 1 using Coupled DEBM and Co-init DEBM with independent DEBM shown in both
(a) and (b), as a function of number of subjects in Group 1. The plots in (c), (d) and (e) show the ordering errors in Group 2
using independent DEBM, Coupled DEBM and Co-init DEBM respectively as a function of number of subjects in Group 1.
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(a) Protective group
(b) Neutral group
(c) Risk group
Figure 6: Experiment 3: Orderings of CSF, global cognition
and volumetric biomarkers in the APOE based protective,
neutral and risk groups along with their uncertainty esti-
mates. Uncertainty in the estimation of the ordering was
measured by 100 repetitions of bootstrapping, in the three
APOE based groups. The color-map is based on the num-
ber of times a biomarker is at a position in 100 repetitions of
bootstrapping. The number of subjects in the three groups
were 75, 411 and 485 respectively. The orderings were ob-
tained using Co-init DEBM.
5. Discussion
DEBM models have been shown to be effective
in determining the temporal cascade of biomarker
abnormality as AD progresses, from cross-sectional
data. In this work, we introduced a novel con-
cept of splitting the different steps of DEBM into
group-specific and group-aspecific parts for coupled
training in stratified population. We considered
two novel variations to split the steps of DEBM
in this manner and through thorough experimen-
tation in simulation datasets we observed that co-
init DEBM helps in obtaining more accurate order-
ings in a stratified population. Using this method,
we estimated the biomarker cascades in AD pro-
gression with protective, neutral and risk alleles of
APOE, based on cross-sectional ADNI data. While
the findings in neutral and risk groups fit the amy-
loid cascade hypothesis of Alzheimer’s disease with
high-confidence (which posits that ABETA accu-
mulation triggers neurodegeneration), the finding
in the protective group shows evidence for an al-
ternative pathway (with relatively low confidence).
In this section, we discuss the insights provided by
the simulation experiments (Section 5.1) used for
method selection as well as the insights into the AD
progression pathways provided by our experiments
on the ADNI dataset (Section 5.2).
5.1. Choice of the method
Coupled DEBM and co-init DEBM both split
DEBM into group-specific and group-aspecific steps
for coupled training of an EBM in stratified popu-
lations. Experiment 1 and 2 showed that coupled
training of the group-aspecific parts of DEBM and
independently training the group-specific parts of
DEBM results in more accurate orderings in the
groups better than the default approach of inde-
pendently training a DEBM model in each group.
While splitting DEBM into group-specific and
group-aspecific parts, we started with the as-
sumption that the latent true normal and abnor-
mal biomarker distributions in the groups are ei-
ther same or similar. The difference between co-
init DEBM and coupled DEBM is that, co-init
DEBM accounts for slight differences in the under-
lying biomarker distributions between the groups
whereas coupled DEBM does not.
The simulation dataset generated in Experi-
ment 1 had the same true normal and abnor-
mal biomarker distributions in the different groups,
from which the simulated subjects were randomly
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(a) Protective group
(b) Neutral group
(c) Risk group
Figure 7: Experiment 4: Orderings of CSF, global cognition and volumetric biomarkers including those of Hippocampus
subfields in the APOE based protective, neutral and risk groups along with their uncertainty estimates. Uncertainty in the
estimation of the ordering was measured by 100 repetitions of bootstrapping, in the 3 APOE based groups. The color-map is
based on the number of times a biomarker is at a position in 100 repetitions of bootstrapping. The biomarkers for hippocampus
subfields are indicated with a prefix of [H] in this figure. The number of subjects in the three groups were 75, 411 and 485
respectively. The orderings were obtained using Co-Init DEBM.
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(a) Protective: Stage vs MMSE (b) Protective: Stage vs ADAS13
(c) Neutral: Stage vs MMSE (d) Neutral: Stage vs ADAS13
(e) Risk: Stage vs MMSE (f) Risk: Stage vs ADAS13
Figure 8: Experiment 5: Correlation of estimated disease stages with MMSE and ADAS scores in the APOE based
protective, neutral and risk groups. The plot on top of each subfigure shows the probability density function of the
disease stages, and the plot on the right of each subfigure shows the probability density function of the cognitive score
in the subfigure. The 2D plot in each subfigure shows the joint density function of the two axes. The line in each
subfigure shows the linear regression of MMSE / ADAS scores with the estimated disease stage and the shaded area
around the line shows its 95% confidence interval. Figures (a),(c) and (e) depict correlation between MMSE score
and obtained disease stages in the three APOE based groups. Figures (b), (d) and (f) depict correlation between
ADAS13 score and the obtained disease stages in the three APOE based groups.
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sampled, aligning well with the assumption of cou-
pled DEBM. However, this did not result in overall
better accuracies for coupled DEBM than that of
co-init DEBM. Co-init DEBM was also more ro-
bust than coupled DEBM as its accuracy was less
dependent on εO, the distance between the ground-
truth orderings in the two groups.
Another observation in Experiment 1, which was
rather counter-intuitive, was that the errors made
by the co-init and coupled DEBM models decreased
as the distance between the ground-truth orderings
in the two groups increased. When the orderings
are further apart, the combined biomarker distri-
butions in CN and AD groups have a larger over-
lap. The non-overlapping initialization (before the
GMM optimization) thus results in the normal and
abnormal distributions to be further apart. We hy-
pothesize that this results in a better estimation
of the mixing parameters during GMM optimiza-
tion and in-turn resulted in more accurate order-
ings, as mixing-parameters are dependent on the
biomarker’s position in the ordering.
In Experiment 2, we checked the performance of
our approaches when the assumption (true normal
and abnormal biomarker distributions being same
across groups) is violated in the dataset. This ex-
periment showed that the orderings obtained using
co-init DEBM are more robust to differences be-
tween the abnormal Gaussians across groups than
those obtained with coupled DEBM. With cou-
pled DEBM, the error increased in the group with
weaker biomarkers i.e., Group 1 in the case of
εG = +0.2d and Group 2 in the case of εG = −0.2d.
This shows that coupled DEBM introduces a sys-
tematic bias in the estimation of ordering that is
detrimental to the group with weaker biomarkers.
Co-init DEBM also showed a similar bias, but to a
much lesser extent.
We hence selected co-init DEBM as the preferred
approach for splitting and performed our analysis
on ADNI dataset using this approach. We expect
that this idea of splitting DEBM into group-specific
and group-aspecific parts can be easily extended to
the EBM introduced by Fonteijn et al. (2012).
5.2. Cascade of biomarker changes in the APOE
based groups
Dividing the total population into groups based
on APOE carriership enabled us to create more
phenotypically homogeneous groups (Weintraub
et al., 2019), each with potentially specific disease
progression timeline. In this section, we discuss our
results in these APOE carriership based groups.
Our finding suggests that among the CSF
biomarkers in the APOE risk and neutral groups,
ABETA abnormality is the earliest biomarker event
followed by PTAU. This fits the amyloid cascade
hypothesis of AD, which posits that ABETA accu-
mulation triggers neurodegeneration (Hardy, 2017).
It also confirms the need for preventing the accu-
mulation of ABETA in high-risk patients. NFL
and NG are late biomarkers in the neutral and risk
groups, which suggests that axonal (Ashton et al.,
2019) and synaptic (Thorsell et al., 2010) degen-
eration do not occur until very late in the disease
process in these groups. NG being abnormal after
PTAU and TAU in the neutral and risk groups is
also consistent with the previous findings that Tau
mediates synaptic damage in AD (Jadhav et al.,
2015).
In the protective group, we found that the ab-
normal NG and PTAU are the earliest CSF events,
even before ABETA becomes abnormal. This could
hint at the existence of an alternative pathway for
the formation of tau tangles in the brain before
ABETA accumulation, as suggested in Weigand
et al. (2019), but needs more extensive validation.
Among the volumetric biomarkers, Entorhinal
cortex is one of the early biomarkers in the
risk group which is supported by the findings
in Huijbers et al. (2014), but is one of the last
biomarkers to become abnormal in the neutral al-
lele. Ventricular volume is a late biomarker in the
risk group but it becomes abnormal quite early
in the neutral group as also observed by Nestor
et al. (2008). Hippocampus volume is the earli-
est biomarker in the risk group, but is a relatively
late biomarker in the neutral and protective groups.
This suggests that incidence of hippocampal spar-
ing AD (Ferreira et al., 2017) could correlate with
APOE carriership.
Volumetric biomarkers of large regions are gener-
ally insensitive to small changes in volume of sub-
parts. Thus to find the earliest regions that are
affected in AD progression, we analyzed the order-
ing of biomarker events while also including hip-
pocampal subfields. Our results suggests that in
the risk group, molecular layer of the subiculum
and CA fields (ML) followed by subiculum and the
tail of the hippocampus are the earliest volumet-
ric biomarker events. Tail of the hippocampus is
not a histologically distinct region but consists of
CA1-4 and dentate gyrus (Iglesias et al., 2015).
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Each of these regions as well as subiculum were
observed to be associated to AD in Parker et al.
(2019). Hippocampal fissure was one of the last
regions to become abnormal. In contrast, in the
neutral group, subiculum and CA1 were the last re-
gions to become abnormal. Parasubiculum was one
of the earliest region to become abnormal in this
group. Parasubiculum as an early biomarker was
also observed in (Zhao et al., 2019) where they re-
ported a significant difference in its volume between
CN and MCI. In the protective group, Parasubicu-
lum, Fissure, Tail and Presubiculum were among
the early volumetric biomarkers. Our findings thus
highlight that Hippocampus subfields are differen-
tially affected due to APOE carriership.
The findings related to these orderings of
biomarker events were validated by correlating the
patient stages derived from these orderings with
MMSE and ADAS13 scores. Patient stages of sub-
jects in all three groups, when used as test-subjects
in a cross-validated manner, showed a significant
correlation (p < 0.001) with these scores. These
correlations validate our findings and suggest that
these genotype-specific disease progression time-
lines could be used for patient monitoring.
6. Conclusion and Future work
We conclude that co-init DEBM provides the
best accuracy and robustness when estimating or-
derings in stratified populations. Future work on
co-init DEBM can focus on extending the approach
for high-dimensional imaging biomarkers (Venka-
traghavan et al., 2019b). This work also pro-
vides groundwork for extending the method to-
wards hypothesis-free, data-driven stratification of
phenotypes.
We gained new insights into the disease progres-
sion timeline of AD in the APOE based risk, neu-
tral and protective groups of APOE. While we ob-
served that the estimated disease progression time-
lines in the risk and neutral groups fit the amy-
loid cascade hypothesis with high confidence, the
estimated time lines in the protective group may
suggest an alternative pathway for the formation
of tau tangles in the brain before amyloid β accu-
mulation, albeit with relatively low condence. We
expect that these genotype-specific disease progres-
sion timelines will benefit patient monitoring in the
future, and may help optimize selection of eligible
subjects for clinical trials.
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